Phoebedel Reyes
Family · Los Angeles, CANPI 1700485265
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (34.5%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by UCB, Inc. at 34.9% of the total. 2025 is the largest year on record at $18,997, more than ten times the $1,113 reported in 2022. Among family clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 258 payments — averaging $100.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$9K
- Argenx US, Inc.$6K
- Sarepta Therapeutics, Inc.$6K
- AstraZeneca$3K
- Biogen$1K
- Genentech, Inc.$216
- plus $726 from 8 others
What the payments were for
- Consulting fees$8,95034%
- Speaking & faculty fees$2,47510%
- Travel & lodging$6,41325%
- Food & beverage$8,13331%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 97 | $9,069 |
| Argenx US, Inc. | 18 | $5,883 |
| Sarepta Therapeutics, Inc. | 25 | $5,750 |
| AstraZeneca | 46 | $2,860 |
| Biogen | 47 | $1,467 |
| Genentech, Inc. | 3 | $216 |
| Genentech USA, Inc. | 2 | $178 |
| NS Pharma, Inc. | 7 | $145 |
| PTC Therapeutics, Inc. | 4 | $109 |
| ITF Therapeutics LLC | 3 | $108 |
| Novartis | 2 | $80 |
| Catalyst Pharmaceuticals, Inc. | 2 | $47 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $31 |
| Neurelis, Inc. | 1 | $28 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$25,971 in reported general payments places this provider in the 95th percentile of 10,634 family providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EvrysdiRisdiplam | 38 | $1,046,734 |
| Mycophenolate Mofetil | 89 | $12,753 |
| Pyridostigmine Bromide | 52 | $4,954 |
| Gabapentin | 30 | $1,458 |
| Mexiletine Hcl | 20 | $1,457 |
| Prednisone | 85 | $701 |
| Clonazepam | 13 | $108 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Genentech USA, Inc.Evrysdi | $178 | $1,046,73438 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,634 family providers in California.
Other family in Los Angeles
- Annette ShonLos Angeles$406K
- Phyllis CasonLos Angeles$187K
- Theodore SolomonLos Angeles$131K
- Angela SarffLos Angeles$51K
- Karla MenjivarLos Angeles$36K
- Janet GripshoverLos Angeles$30K
- Jualynda SmithLos Angeles$28K
- Ayana ElliottLos Angeles$25K
- Lori RobertsonChino Hills$475K
- Lisa HigginsHanford$311K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.